ESTRO 2024 - Abstract Book

S403

Brachytherapy - Urology

ESTRO 2024

Results:

The average age was 67 years (47-84). The majority of cases were classified as low (n=92) or intermediate (n=129) risk. High-risk patients (n=37) accounted for a smaller proportion. Only 31 patients received ADT; median duration of therapy was 3 months. Patients had a very favorable profile of acute and late GI and GU toxicities, namely 1.2% severe (G≥3) acute or late GU toxicities and no (0%) severe (G≥3) acute or late GI toxicities. Moreover, approximately 80% of the patients had only Grad 0 or 1 GU toxicities and 96% of the patients had no GI toxicities at all. The 5-year biochemical recurrence-free survival (bRFS) of patients depended on the risk group of patients, and was 93.8% in low risk, 87.7% in intermediate risk, and 63.6% in high risk.

Conclusion:

The effectiveness of the therapy has already been summarized previously in a number of meta-analyses as well as a very favorable profile of acute and late toxicities (1, 2). We summarized all toxicities in our data, showing extreme favorable profile by maintaining good effectivity providing good quality of life for our patients. HDR-BT of the prostate is an effective therapy, which shows a favorable profile of treatment-associated toxicities.

Keywords: Monotherapy, quality of life

References:

1. Anderson EM, Kim S, Sandler HM, Kamrava M. High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. J Contemp Brachytherapy. 2021 Aug;13(4):365 372. 2. Tsang YM, Tharmalingam H, Belessiotis-Richards K, Armstrong S, Ostler P, Hughes R, Alonzi R, Hoskin PJ. Ultra hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiother Oncol. 2021 May;158:184-190.

690

Digital Poster

Brachytherapy for favorable prostate cancer in men up to 60 years of age: long term follow up

Juliette JACQUES 1 , Nassim SAHKI 2 , Emilie MEKNACI 1 , Pascal ESCHWEGE 3 , Didier PEIFFERT 1 , Nicolas DEMOGEOT 1

1 Institut de Cancérologie de Lorraine, Department of Radiotherapy, Nancy, France. 2 Institut de Cancérologie de Lorraine, Methodology Biostatistuc unit, Nancy, France. 3 Institut de Cancérologie de Lorraine, Department of Surgery, Nancy, France